Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study
Open Access
- 1 January 2023
- journal article
- research article
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (44) , e346
Abstract
Kang H, et al. J Korean Med Sci. 2023 Oct;38:e346. https://doi.org/10.3346/jkms.2023.38.e346Keywords
Funding Information
- Korea Institute of Drug Safety and Risk Management (20210428742-00)
This publication has 22 references indexed in Scilit:
- Remdesivir in Patients With Estimated GFR <30 ml/min per 1.73 m2 or on Renal Replacement TherapyKidney International Reports, 2021
- Safety of Remdesivir in Patients With Acute Kidney Injury or CKDKidney International Reports, 2021
- Remdesivir for 5 or 10 Days in Patients with Severe Covid-19New England Journal of Medicine, 2020
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020
- Use of remdesivir in the presence of elevated LFTs for the treatment of severe COVID-19 infectionBMJ Case Reports, 2020
- Efficacy and safety of remdesivir in hospitalized Covid‐19 patients: Systematic review and meta‐analysis including network meta‐analysisReviews in Medical Virology, 2020
- Safety profile of the antiviral drug remdesivir: An updateBiomedicine & Pharmacotherapy, 2020
- Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19JAMA, 2020
- Remdesivir: A Review of Its Discovery and Development Leading to Emergency Use Authorization for Treatment of COVID-19ACS Central Science, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020